About this trial
This randomized, double-blind, placebo-controlled crossover trial investigates the effects of three different caffeine supplementation strategies on resistance training-induced adaptations in 180 caffeine-naive, inactive young adult males. Participants will undergo two 4-week supervised resistance training programs separated by a 2-week washout/crossover period. The three caffeine strategies are: (1) constant daily low-moderate dosing (3 mg/kg/day), (2) gradually escalating dose (3 to 6 mg/kg across weeks), and (3) training-day-only caffeine (3 mg/kg/day). Primary outcomes include non-invasive measures of integrated anabolism and hypertrophy (D2O-derived plasma proteomic fractional synthesis rate, DXA muscle volume) and strength metrics. Secondary outcomes include hormonal responses (insulin, cortisol, testosterone, IGF-1), sleep/recovery parameters, and adverse effects.
Eligibility criteria
Qualifiers
Male sex and age between 18-30 years
No history of caffeine use or very low habitual intake (<50 mg/day)
No participation in a regular resistance training program in the past 6 months
Body mass index (BMI) between 18.5-30 kg/m2
Disqualifiers
Presence of cardiovascular, metabolic, renal, hepatic, or other serious chronic diseases
Diagnosed psychiatric disorders or severe caffeine intolerance/allergy
Use of medications affecting caffeine metabolism or muscle anabolism (e.g., beta-blockers, antidepressants, anabolic steroids)
Musculoskeletal injuries that prevent safe resistance training
Trial design
Treatments tested in this trial
- Caffeine (Constant Daily Dose)
- Placebo (Constant Daily Dose)
- Caffeine (Escalating Dose)
- Placebo (Escalating Dose)
- Caffeine (Training Days Only)
- Placebo (Training Days Only)
Treatment groups
6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Istanbul University - Cerrahpasa
Lead sponsor
İstanbul Yeni Yüzyıl Üniversitesi
Collaborator